| Literature DB >> 25101132 |
Olufunmiso O Olajuyigbe1, Roger M Coopoosamy1.
Abstract
Background. This study was aimed at evaluating the antibacterial activity of the acetone extract of A. mearnsii and its interactions with antibiotics against some resistant bacterial strains. Methods. The antibacterial susceptibility testing was determined by agar diffusion and macrobroth dilution methods while the checkerboard method was used for the determination of synergy between the antibiotics and the extract. Results. The results showed that the susceptibility of the different bacterial isolates was concentration dependent for the extract and the different antibiotics. With the exception of S. marcescens, the inhibition zones of the extract produced by 20 mg/mL ranged between 18 and 32 mm. While metronidazole did not inhibit any of the bacterial isolates, all the antibiotics and their combinations, except for ciprofloxacin and its combination, did not inhibit Enterococcus faecalis. The antibacterial combinations were more of being antagonistic than of being synergistic in the agar diffusion assay. From the macrobroth dilution, the extract and the antibiotics exerted a varied degree of inhibitory effect on the test organisms. The MIC values of the acetone extract which are in mg/mL are lower than those of the different antibiotics which are in μg/mL. From the checkerboard assay, the antibacterial combinations showed varied degrees of interactions including synergism, additive, indifference, and antagonism interactions. While antagonistic and additive interactions were 14.44%, indifference interaction was 22.22% and synergistic interaction was 37.78% of the antibacterial combinations against the test isolates. While the additivity/indifference interactions indicated no interactions, the antagonistic interaction may be considered as a negative interaction that could result in toxicity and suboptimal bioactivity. Conclusion. The synergistic effects of the herbal-drug combinations may be harnessed for the discovery and development of more rational evidence-based drug combinations with optimized efficiency in the prevention of multidrug resistance and therapy of multifactorial diseases.Entities:
Year: 2014 PMID: 25101132 PMCID: PMC4102002 DOI: 10.1155/2014/423751
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Average inhibition zones (±1.0 mm) produced by acetone extract of Acacia mearnsii and their different combinations.
| AMA alone | Ery alone | Combined AMA + Ery | Tet alone | Combined AMA + Tet | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 | 10 | 20 | 62.5 | 125 | 250 | 1.25 + 62.5 | 2.5 + 125 | 5 + 250 | 62.5 | 125 | 250 | 1.25 + 62.5 | 2.5 + 125 | 5 + 250 | |
| mg/mL |
| mg/mL + |
| mg/mL + | |||||||||||
|
| 13 | 15 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 22 | 24 | 27 | 22 | 25 | 28 |
|
| 17 | 20 | 23 | 25 | 28 | 30 | 20 | 23 | 27 | 25 | 27 | 31 | 25 | 28 | 32 |
|
| 16 | 18 | 21 | 26 | 30 | 34 | 21 | 23 | 25 | 22 | 25 | 28 | 25 | 27 | 30 |
|
| 0 | 14 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 18 | 22 | 15 | 18 | 22 |
|
| 17 | 20 | 23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 17 | 19 | 21 | 28 | 30 | 33 | 25 | 26 | 28 | 31 | 34 | 36 | 30 | 34 | 38 |
|
| 25 | 29 | 32 | 0 | 0 | 0 | 0 | 14 | 16 | 29 | 31 | 33 | 31 | 33 | 36 |
|
| 14 | 16 | 19 | 20 | 23 | 27 | 17 | 20 | 24 | 22 | 26 | 30 | 27 | 30 | 33 |
|
| 18 | 21 | 23 | 22 | 23 | 25 | 22 | 24 | 25 | 23 | 26 | 28 | 25 | 27 | 30 |
|
| 20 | 22 | 24 | 25 | 27 | 30 | 15 | 27 | 31 | 22 | 23 | 25 | 25 | 26 | 28 |
|
| |||||||||||||||
| AMA alone | Met alone | Combined AMA + Met | Amx alone | Combine AMA + Amx | |||||||||||
| 5 | 10 | 20 | 62.5 | 125 | 250 | 1.25 + 62.5 | 2.5 + 125 | 5 + 250 | 62.5 | 125 | 250 | 1.25 + 62.5 | 2.5 + 125 | 5 + 250 | |
| mg/mL |
| mg/mL + |
| mg/mL + | |||||||||||
|
| |||||||||||||||
|
| 13 | 15 | 18 | 0 | 15 | 20 | 0 | 15 | 17 | 22 | 24 | 27 | 22 | 24 | 27 |
|
| 17 | 20 | 23 | 0 | 0 | 0 | 17 | 20 | 22 | 15 | 18 | 20 | 18 | 20 | 22 |
|
| 16 | 18 | 21 | 0 | 0 | 0 | 14 | 17 | 19 | 20 | 21 | 22 | 19 | 20 | 22 |
|
| 0 | 14 | 18 | 0 | 0 | 0 | 0 | 14 | 18 | 14 | 17 | 20 | 17 | 20 | 23 |
|
| 17 | 20 | 23 | 0 | 0 | 0 | 17 | 20 | 23 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 17 | 19 | 21 | 0 | 0 | 0 | 16 | 21 | 24 | 28 | 30 | 32 | 27 | 29 | 32 |
|
| 25 | 29 | 32 | 0 | 0 | 0 | 0 | 15 | 18 | 28 | 32 | 34 | 30 | 35 | 37 |
|
| 14 | 16 | 19 | 0 | 0 | 0 | 11 | 14 | 16 | 28 | 32 | 36 | 33 | 36 | 40 |
|
| 18 | 21 | 23 | 0 | 0 | 0 | 14 | 16 | 18 | 18 | 20 | 22 | 20 | 23 | 2 |
|
| 20 | 22 | 24 | 0 | 0 | 0 | 15 | 18 | 20 | 19 | 20 | 23 | 22 | 25 | 26 |
|
| |||||||||||||||
| AMA alone | Cip alone | Combined AMA + Cip | Nal alone | Combined AMA + Nal | |||||||||||
| 5 | 10 | 20 | 1.25 | 2.5 | 5 | 1.25 + 1.25 | 2.5 + 2.5 | 5 + 5 | 62.5 | 125 | 250 | 1.25 + 62.5 | 2.5 + 125 | 5 + 250 | |
| mg/mL |
| mg/mL + |
| mg/mL + | |||||||||||
|
| |||||||||||||||
|
| 13 | 15 | 18 | 30 | 33 | 35 | 20 | 24 | 27 | 25 | 27 | 30 | 20 | 24 | 28 |
|
| 17 | 20 | 23 | 20 | 24 | 27 | 18 | 22 | 27 | 20 | 25 | 28 | 17 | 19 | 22 |
|
| 16 | 18 | 21 | 21 | 25 | 28 | 18 | 21 | 25 | 24 | 27 | 30 | 17 | 19 | 24 |
|
| 0 | 14 | 18 | 32 | 35 | 40 | 26 | 29 | 32 | 27 | 30 | 33 | 25 | 28 | 30 |
|
| 17 | 20 | 23 | 33 | 38 | 42 | 21 | 24 | 28 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 17 | 19 | 21 | 30 | 35 | 38 | 25 | 27 | 30 | 0 | 0 | 0 | 15 | 18 | 21 |
|
| 25 | 29 | 32 | 32 | 37 | 40 | 15 | 16 | 18 | 29 | 32 | 34 | 24 | 26 | 29 |
|
| 14 | 16 | 19 | 23 | 28 | 32 | 19 | 24 | 27 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 18 | 21 | 23 | 25 | 26 | 28 | 23 | 25 | 27 | 24 | 26 | 30 | 23 | 25 | 29 |
|
| 20 | 22 | 24 | 28 | 30 | 33 | 30 | 32 | 35 | 18 | 20 | 22 | 20 | 21 | 23 |
|
| |||||||||||||||
| AMA alone | Chl alone | Combined AMA + Chl | Kan alone | Combined AMA + Kan | |||||||||||
| 5 | 10 | 20 | 62.5 | 125 | 250 | 1.25 + 62.5 | 2.5 + 125 | 5 + 250 | 62.5 | 125 | 250 | 1.25 + 62.5 | 2.5 + 125 | 5 + 250 | |
| mg/mL |
| mg/mL + |
| mg/mL + | |||||||||||
|
| |||||||||||||||
|
| 13 | 15 | 18 | 22 | 25 | 30 | 16 | 19 | 21 | 23 | 25 | 28 | 16 | 20 | 23 |
|
| 17 | 20 | 23 | 25 | 28 | 30 | 19 | 20 | 24 | 24 | 27 | 30 | 15 | 17 | 21 |
|
| 16 | 18 | 21 | 25 | 28 | 30 | 20 | 22 | 26 | 22 | 25 | 28 | 20 | 23 | 26 |
|
| 0 | 14 | 18 | 0 | 0 | 0 | 16 | 20 | 24 | 23 | 25 | 28 | 19 | 24 | 26 |
|
| 17 | 20 | 23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 17 | 19 | 21 | 21 | 25 | 28 | 17 | 20 | 23 | 18 | 22 | 27 | 22 | 26 | 28 |
|
| 25 | 29 | 32 | 30 | 32 | 35 | 23 | 27 | 30 | 28 | 30 | 32 | 29 | 32 | 34 |
|
| 14 | 16 | 19 | 29 | 30 | 35 | 20 | 24 | 27 | 22 | 25 | 28 | 20 | 24 | 26 |
|
| 18 | 21 | 23 | 25 | 28 | 30 | 25 | 26 | 28 | 23 | 26 | 28 | 25 | 27 | 29 |
|
| 20 | 22 | 24 | 25 | 27 | 29 | 25 | 26 | 28 | 19 | 23 | 25 | 23 | 25 | 27 |
AMA: acetone extract of A. mearnsii; Ery: erythromycin; Tet: tetracycline; Met: metronidazole; Cip: ciprofloxacin; Nal: nalidixic acid; Chl: chloramphenicol; Kan: kanamycin.
Antibacterial effects of acetone stem bark extract of A. mearnsii and the different first-line antibiotics.
| Tested bacterial isolates | Minimum inhibitory concentrations (MIC) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| AMA | Ery | Tet | Met | Amx | Cip | Nal | Chl | Kan | |
| mg/mL |
| ||||||||
|
| 0.625 | 0.391R | 0.976S | 31.250R | 3.906S | 0.039S | 1.953S | 3.906S | 125R |
|
| 0.156 | 0.098S | 0.244S | 31.250R | 7.813R | 0.078S | 15.625S | 3.906S | 125R |
|
| 0.156 | 0.195S | 0.488S | 15.625R | 3.906S | 0.156S | 7.813S | 3.906S | 31.25R |
|
| 0.625 | 3.125R | 15.625R | 31.250R | 31.25R | 0.078S | 1.953S | 0.977S | 1.953S |
|
| 0.625 | 12.500R | 15.625R | 62.500R | 0.977S | 0.313S | 62.500R | 31.250R | 500R |
|
| 0.078 | 0.195S | 0.976S | 15.625R | 0.977S | 0.078S | 62.500R | 7.813R | 15.625R |
|
| 0.313 | 6.250R | 0.244S | 31.250R | 0.977S | 0.0195S | 7.813S | 3.906S | 15.625R |
|
| 0.039 | 0.391R | 31.250R | 31.250R | 0.488S | 1.250R | 62.500R | 1.953S | 250R |
|
| 0.156 | 0.048S | 0.488S | 62.500R | 0.244S | 0.0195S | 62.500R | 31.250R | 31.25R |
|
| 0.078 | 0.195S | 0.488S | 62.500R | 250.000R | 0.039S | 62.500R | 7.813 | 15.625R |
S: sensitive; R: resistant; AMA: acetone extract of A. mearnsii; Ery: erythromycin; Tet: tetracycline; Met: metronidazole; Cip: ciprofloxacin; Nal: nalidixic acid; Chl: chloramphenicol; Kan: kanamycin.
Fractional inhibitory concentrations of acetone stem bark extract of A. mearnsii in combination with the different antibiotics.
| Tested bacterial isolates | Fractional inhibitory concentrations (FIC) | |||||||
|---|---|---|---|---|---|---|---|---|
| AMA + Ery | FICI | AMA + Tet | FICI | AMA + Met | FICI | AMA + Amx | FICI | |
| mg/mL + | mg/mL + | mg/mL + | mg/mL + | |||||
|
| 0.625/6.25 | 17.00Ant | 0.0098/0.244 | 0.266 Syn | 0.313/15.625 | 1.00 Add | 0.156/7.813 | 1.25 Ind |
|
| 0.0098/0.098 | 1.63 Ind | 0.00122/0.061 | 0.258 Syn | 0.156/7.813 | 1.25 Ind | 0.078/3.906 | 1.000 Add |
|
| 0.0049/0.049 | 0.06 Syn | 0.00122/0.061 | 0.133 Syn | 0.625/31.250 | 6.00 Ant | 0.039/1.953 | 0.750 Add |
|
| 0.625/6.25 | 3.00 Ind | 0.0781/3.906 | 0.37 Syn | 0.625/31.250 | 2.00 Ind | 0.156/7.813 | 0.500 Syn |
|
| 0.156/1.563 | 0.38 Syn | 0.313/15.625 | 1.5 Ind | 0.625/31.250 | 1.50 Ind | 0.0049/0.244 | 0.258 Syn |
|
| 0.0049/0.049 | 0.31 Syn | 0.0098/0.244 | 0.375 Syn | 0.625/31.250 | 10.00 Ant | 0.0049/0.244 | 0.312 Syn |
|
| 0.1563/1.953 | 0.81Add | 0.00122/0.061 | 0.254 Syn | 0.625/31.250 | 3.00 Ind | 0.0049/0.244 | 0.265 Syn |
|
| 0.0391/0.391 | 2.00 Ind | 0.0781/3.906 | 2.128 Ind | 0.313/15.625 | 10.00 Ant | 0.0024/0.122 | 0.312 Syn |
|
| ≤0.0003/0.003 | 0.08 Syn | 0.0049/0.122 | 0.281 syn | 0.078/3.906 | 0.50 Syn | 0.006/0.030 | 0.165 Syn |
|
| 0.0098/0.098 | 0.38 Syn | 0.156/7.813 | 18.01 Ant | 0.313/15.625 | 4.25 Ant | 0.0391/1.953 | 0.509 Add |
|
| ||||||||
| Tested bacterial isolates | Fractional inhibitory concentrations (FIC) | |||||||
| AMA + Cip | FICI | AMA + Nal | FICI | AMA + Chl | FICI | AMA + Kan | FICI | |
| mg/mL + | mg/mL + | mg/mL + | mg/mL + | |||||
|
| ||||||||
|
| 0.0098/0.0098 | 0.266 Syn | 0.078/3.906 | 2.125 Ind | 0.0391/1.953 | 0.563 Add | 0.156/7.813 | 0.313 Syn |
|
| 0.0781/0.0781 | 1.500 Ind | 0.313/15.625 | 3.000 Ind | 0.0195/0.977 | 0.375 Syn | 0.078/3.906 | 0.531 Add |
|
| 0.0781/0.0781 | 1.000 Add | 0.156/7.813 | 2.000 Ind | 0.0195/0.977 | 0.375 Syn | 0.0391/1.953 | 0.312 Syn |
|
| 0.0098/0.0098 | 0.250 Syn | 0.039/1.953 | 1.062 Ind | 0.0098/0.488 | 0.512 Add | 0.078/3.906 | 2.125 Ind |
|
| 1.25/1.25 | 6.000 Ant | 0.625/31.250 | 1.500 Ind | 0.0781/3.906 | 0.250 Syn | 1.250/62.500 | 2.125 Ind |
|
| 0.0098/0.0098 | 0.251 Syn | 0.156/7.813 | 2.125 Ind | 0.0391/1.953 | 0.750 Add | 0.313/15.625 | 5.000 Ant |
|
| 0.0049/0.0049 | 0.27 Syn | 0.039/1.953 | 0.37 Syn | 0.0195/0.977 | 0.44 Syn | 0.0097/0.488 | 0.062 Syn |
|
| 0.3125/0.3125 | 8.250 Ant | 0.156/7.813 | 4.125 Ant | 0.0391/1.953 | 2.000 Ind | 0.625/31.500 | 16.13 Ant |
|
| 0.0049/0.0049 | 0.283 Syn | 0.078/3.906 | 0.562 Add | 0.0781/3.906 | 0.626 Add | 0.0391/1.953 | 0.312 Syn |
|
| 0.0098/0.0098 | 0.377 Syn | 0.313/15.625 | 4.250 Ant | 0.0391/1.953 | 0.750 Add | 0.313/15.625 | 5.000 Ant |
AMA: acetone extract of A. mearnsii; Ery: erythromycin; Tet: tetracycline; Met: metronidazole; Cip: ciprofloxacin; Nal: nalidixic acid; Chl: chloramphenicol; Kan: kanamycin; FICI: fractional inhibitory concentration indices.